Jun. 30 at 12:12 PM
$AMGN lets wait for now; ditto
$LLY $NVO
seeking alpha 6/30 early am report:
$IVBXF premarket 6/30 8:03 am EDT -2.13% TO 9.87
OBTAINED REgULATORY APPROVAL last week for its obesity treatment, MASDUTIDE, a significant milestone in
$FXI $MCHI pus to tackle risin obesity & diabetes rates thru home grown innovation.
$IVBXF first licensed MASDUTIDE from
$LLY in 2019 (wait ?!?! what) when the drug was in mid-stage testing. The Chinese co ran large clinical trials suggesting that in local patients, it appeared just as effective as ZepBound by
$LLY in helpin patients lose weight